Osagie Imasogie

Mr. Imasogie is the Co-Founder and Senior Managing Partner of PIPV Capital with over 30 years of experience in the fields of law, finance and business management, healthcare, and the pharmaceutical industry.  Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures in which he led his team in investing GSK R&D non-progressed assets into various companies and/or as the basis of starting new companies.  Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham.

He has served as the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals.  He also previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing, and Generic Drug Divisions.  Osagie has been a serial entrepreneur and has been founder and former CEO and/or Chairman of multiple life sciences companies, including Iroko Pharmaceuticals, iCeutica, Churchill Pharmaceuticals, Ception Therapeutics, and Trigenesis Therapeutics.

Osagie is active in charitable, community, and academic pursuits and serves as a member of the Executive Committee of the Board of the Philadelphia Orchestra and the Philadelphia Museum of Art.  Osagie is an Adjunct Professor at the University of Pennsylvania Law School and also serves on the Law School’s Board of Overseers and has been designated the incoming Chairman of the Board.  In addition, he is a member of the Board of Trustees of the University of Pennsylvania and serves as a member of its Executive Committee in addition to having been a former Chairman of the Budget & Finance Committee.  Osagie holds graduate degrees from the University of Pennsylvania Law School and the London School of Economics and is a member of the New York State Bar in addition to other Bars.